CPT1A and metabolic dysfunction-associated steatotic liver disease: CP improved glucose homeostasis through regulating gut microbiota, while the anti-NAFLD effect of CP mainly relied on activated FAO by increasing the nuclear localization of PPARα and the expression of CPT1α.